3D InSight™ | 3D In Vitro MASLD Model for Liver Disease Discovery
Understand the biology of fatty liver disease and screen for small molecules and biologicals - all in the same
3D In Vitro MASLD discovery platform
3D In Vitro MASLD Model
Metabolic dysfunction-associated steatotic liver disease or MASLD (renamed from NAFLD in June 2023) encompasses patients who have hepatic steatosis and have at least one of five cardiometabolic risk factors.
Leveraging InSphero's market-leading 3D InSight™ MASH model, our 3D In Vitro MASLD model offers equivalent advantages for fatty liver disease research. Experience a high-quality, scalable, and human-relevant 3D cell culture disease model that generates precise insights and facilitates efficient research throughput. Rely on our expertise in creating primary-cell spheroid models and inducing specific disease phenotypes, enabling us to tailor solutions to your needs - fast and efficient for early-stage decision-making.
Why MASLD Screening with InSphero?
Discover a top-tier 3D cell culture disease model that is scalable and closely mimics human biology, providing accurate insights for enhanced efficiency. This advanced 3D in vitro MASLD model streamlines your research process, ensuring precise and effective decisions early in the drug development.
Predictive and robust human 3D in vitro MASLD model
As complex as necessary and as simple as possible - our research credo at work. Based on co-culturing fatty liver disease relevant primary cells, our model accurately mimics MASLD
Continuity from screening to mechanistic research
Our MASLD model is great for mechanistic research, as well as for automated screening, compatible with all platforms
Understand the impact of genetic variants (SNPs)
3D InSight™ MASLD models are available in multi-donor form or based on single donors including metabolically relevant SNPs (e.g., PNPLA3, HSD17B13)
10x faster results get you closer to breakthrough therapies
10x faster: that is the time you save going <i>in vitro</i> instead of animal models. Faster data, more insights, quicker iterations to find and assess your compounds
Our Process in MASLD Screening
3D InSight™ Human Liver Microtissues formation
Primary human hepatocytes (PHHs), Kupffer cells, and liver endothelial cells (LECs)
Lipid loading
Using an optimized treatment with free fatty acids and elevated sugar concentration
Compound dosing
Multiple compound addition steps to mimic regular intake
Multiparametric readouts
Quantification of lipid content using biochemical or advanced imaging assays
